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CORRESPONDENCE
Letters to the Editor
A Call for Development
of Comprehensive
Therapy for Dyslipidemia
Treatment of hyperlipidemia with statins has become an integral
part of management of vascular disease today. However, numerous
gray areas exist in the treatment algorithm. The meta-analysis by
Cannon et al. (1) refers to usage of high-dose statin therapy for
low-density lipoprotein (LDL) reduction in the treatment of
cardiovascular diseases. The title of the study uses the term
“Intensive Versus Moderate Statin Therapy,” which apparently is a
new term being coined for high-dose statin therapy. None of the
trials included in the meta-analysis use this term to define the dose
of atorvastatin. In all these trials the prime focus was the level of LDL
achieved and event reduction following that. The atorvastatin dosage
has never been shown to be an independent predictor of long-term
outcome in multivariate analysis. Thus, any dose of atorvastatin or
any other statin that achieves the desired level of LDL of about 70
mg/dl would be considered as optimal statin therapy according to
the current knowledge. Whether the term “intensive” relates to a
high dose of atorvastatin or to a dose of statin that reduces LDL
to about 70 mg/dl is not clear. Hence, the new term of “intensive
statin therapy” is probably not required in today’s clinical jargon.
Whether adequate LDL reduction if achieved using a smaller
dose of statins will confer similar benefit as that with high-dose
statins is not clear due to lack of data. As the pleiotropic effect
cannot be easily measured in clinical practice, the real target for a
clinician today is LDL cholesterol. Most of the large-scale trials
also use the same target and compare the long-term outcomes with
LDL reduction or levels achieved. It would be interesting to
perform a subgroup analysis of patients receiving 10 mg of
atorvastatin and reaching an LDL target of 70 mg/dl in the trials
included in the researchers’ meta-analysis.
It is also very important to understand the same dose of a drug
may not be required in all races to achieve the desired effect. In
clinical practice in India, most of our colleagues have been able to
maintain LDL levels close to 70 mg/dl with much lower doses of
atorvastatin. As of today no important trial data is available to us
from the region, and thus we rely heavily on Western literature. In
this case, what would be an “intensive statin therapy” for an Asian
Indian remains a very difficult question to answer. Thus, a term of
“optimal lipid-lowering therapy” seems more useful and less
confusing than intensive statin therapy.
Low high-density lipoprotein (HDL) is another important
contributor to development of atherosclerotic vascular disease. In
fact, rapid regression of atheroma has only been shown with
infusion of apolipoprotein A-I milano (2). Further, results from
the MIRACL (Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering) study (3) involving 3,086 patients have
shown that HDL and not LDL cholesterol levels influence
short-term prognosis after acute coronary syndrome (ACS). It is
also documented that HDL modulation is better with lower doses
of atorvastatin than with higher doses and even better when
low-dose atorvastatin is combined with ezetimibe.
Reduction in C-reactive protein is probably the only measurable
pleiotropic effect of statins. Comparable C-reactive protein reduc-
tion has also been shown with combination of low-dose simvasta-
tin and ezetimibe to that of high-dose atorvastatin, although in a
short-term study (4). Reduction in LDL with a combination of
low-dose atorvastatin and ezetimibe has been comparable to that
with high-dose atorvastatin alone, again in a short-term study (5).
In light of these facts, it is very important that we develop a
comprehensive hyperlipidemia therapy that encompasses adequate
LDL reduction along with reduction in total cholesterol and
triglycerides and elevation of HDL at the same time, rather than
harping on high-dose statin therapy.
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Reply
We would like to thank Drs. Deshpande, Mardikar, and Deo for
their important comments regarding our study (1). The term
“intensive” statin therapy has recently been used to identify statin
regimens that lower low-density lipoprotein cholesterol (LDL-C)
by approximately 50%, as we did in the PROVE IT–TIMI-22
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